Genprex to present TUSC2 gene therapy research on cellular aging at GSA meeting
GNPX•Genprex will present research on TUSC2 gene therapy and cellular resilience at the Gerontological Society of America’s annual scientific meeting on Nov. 4, 2026. The findings could inform applications beyond oncology, but more research is needed to determine whether they support therapeutic development.
1. Research presentation
Genprex will present research conducted with Meharry Medical College on a cellular-resilience response to TUSC2 gene therapy in humans at the Gerontological Society of America’s annual scientific meeting on Nov. 4, 2026. TUSC2 is used in Genprex’s cancer candidate Reqorsa. The findings could inform potential applications beyond oncology, but additional research is needed to determine whether they support therapeutic development.
